01AnaptysBio reported Q3 earnings per share of $0.11, missing the consensus estimate of $0.51 by $0.40, representing a 78% shortfall.
02Revenue came in at $30.3M versus the estimated $33.2M, indicating the company missed on both earnings and top-line expectations.
03The stock currently trades at $45.45 with a market capitalization of $1.5B after the earnings miss.
04AnaptysBio's earnings have been volatile, with Q1 2026 showing a $1.84 loss versus a $0.66 expected loss, followed by a $1.58 beat in Q4 2026.
Earnings Results
AnaptysBio (NASDAQ:ANAB) reported quarterly earnings results on November 12, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $0.11, missing the consensus estimate of $0.51 by $0.40 per share. Revenue came in at $30.3M, missing the estimate of $33.2M.
Company Overview
AnaptysBio's stock moved following the earnings release. The stock currently trades at $45.45 with a market capitalization of $1.5B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 78% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking AnaptysBio should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.